Afecta Pharma

Afecta Pharma is a specialty pharmaceutical company focused on developing improved versions of existing drugs using its proprietary drug delivery technologies. The company primarily utilizes the FDA's 505(b)(2) regulatory pathway to accelerate the development of therapies with enhanced efficacy, safety, and patient compliance. Its pipeline includes candidates for pain management, central nervous system disorders, and oncology. Afecta's core expertise lies in formulation science and optimizing the pharmacokinetic profiles of established active pharmaceutical ingredients. The company's lead candidate, AF-102, is a novel formulation designed for the treatment of acute and chronic pain. By leveraging its AF-DDS platform, Afecta aims to address significant unmet needs in the global healthcare market.